Yeruva Sri L H, Paul Yonette, Oneal Patricia, Nouraie Mehdi
a Department of Internal Medicine, Division of Hematology/Oncology , Howard University Hospital , Washington , DC , USA.
b Department of Medicine and Vascular Medicine Institute , University of Pittsburgh , Pittsburgh , PA , USA.
Hemoglobin. 2016 Sep;40(5):295-299. doi: 10.1080/03630269.2016.1224766. Epub 2016 Sep 18.
Renal dysfunction in sickle cell disease is not only a chronic comorbidity but also a mortality risk factor. Though renal dysfunction starts early in life in sickle cell patients, the predictors that can identify sickle cell disease patients at risk of developing renal dysfunction is not known. We used the Truven Health MarketScan Medicaid Databases from 2007 to 2012. Incidence of new acute renal failure (ARF) and chronic kidney disease (CKD) was calculated in this cohort. There were 9481 patients with a diagnosis of sickle cell disease accounting for 64,201 hospital admissions, during the study period. Both ARF and CKD were associated with higher risk of inpatient mortality, longer duration of the hospital stay and expensive hospitalizations. The yearly incidence of new ARF in sickle cell disease patients was 1.4% and annual CKD incidence was 1.3%. The annual rate of new ARF and CKD in the control group was 0.4 and 0.6%, respectively. The most important predictors of new CKD were proteinuria, ARF and hypertension. Chronic kidney disease, hypertension and sickle cell crisis were the most important predictors of new ARF. The annual rate of incidences of ARF and CKD were 2- to 3-fold higher in sickle cell disease compared to the non sickle cell disease group. Besides the common risk factors for renal disease in the general population, it is imperative to monitor the sickle cell disease patients with more severe disease to prevent them from developing renal dysfunction.
镰状细胞病中的肾功能不全不仅是一种慢性合并症,也是一个死亡风险因素。尽管镰状细胞病患者在生命早期就开始出现肾功能不全,但尚不清楚哪些预测因素能够识别有发生肾功能不全风险的镰状细胞病患者。我们使用了2007年至2012年的Truven Health MarketScan医疗补助数据库。在该队列中计算了新发性急性肾衰竭(ARF)和慢性肾脏病(CKD)的发病率。在研究期间,有9481例诊断为镰状细胞病的患者,共计64201次住院。ARF和CKD均与住院死亡率较高、住院时间较长以及住院费用昂贵相关。镰状细胞病患者中新发性ARF的年发病率为1.4%,CKD的年发病率为1.3%。对照组中新发性ARF和CKD的年发病率分别为0.4%和0.6%。新发性CKD的最重要预测因素是蛋白尿、ARF和高血压。慢性肾脏病、高血压和镰状细胞危象是新发性ARF的最重要预测因素。与非镰状细胞病组相比,镰状细胞病中ARF和CKD的年发病率高出2至3倍。除了一般人群中常见的肾脏疾病风险因素外,对病情更严重的镰状细胞病患者进行监测以防止他们发生肾功能不全至关重要。